Engineered cells take on hard-to-treat blood cancers in early trial

This early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem cells to help rebuild healthy blood cells. The main goals are to check safety and find the best dose, not to cure the disease.